...
首页> 外文期刊>Nuclear Medicine and Biology >Synthesis and biodistribution of a Lipophilic 64Cu-labeled monocationic Copper(II) complex.
【24h】

Synthesis and biodistribution of a Lipophilic 64Cu-labeled monocationic Copper(II) complex.

机译:亲脂性64Cu标记的单阳离子铜(II)配合物的合成和生物分布。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The lipophilic, monocationic copper(II) complex of the diiminedioxime ligand 2,10-di-n-butyl-3,9-dimethyl-1,4,8,11-tetraazaundeca-1,3,8,10-tetraen-1,11 -dione dioxime was synthesized and labeled with 64Cu. The biological properties of the 64Cu-labeled complex were measured in vivo and in vitro. In vivo, the complex shows uptake by the heart similar to that of 99mTc-tetrofosmin. In vitro, its uptake by multidrug resistant and non-resistant MES-SA tumor cells parallels that of 99mTc-MIBI, a well-characterized marker of multidrug resistance. These results suggest that this class of copper complexes may form the basis for the development of a 64Cu PET radiopharmaceutical for the functional imaging of multidrug resistance and/or myocardial perfusion.
机译:二亚胺二肟配体2,10-二正丁基-3,9-二甲基-1,4,8,11-四氮杂双烯-1,3,8,10-四烯-1的亲脂性单阳离子铜(II)络合物合成了11,1-二酮二肟,并用64Cu标记。在体内和体外测量64Cu标记的复合物的生物学特性。在体内,该复合物显示出对心脏的吸收,类似于99mTc-tetrofosmin。在体外,多药耐药性和非耐药性MES-SA肿瘤细胞对它的摄取与99mTc-MIBI相似,99mTc-MIBI是一种公认​​的多药耐药性标志物。这些结果表明,这类铜络合物可能构成开发64Cu PET放射性药物的基础,该药物可用于多药耐药性和/或心肌灌注的功能成像。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号